# Considerations for Complying with 21 CFR 211110 - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-complying-with-21-cfr-211110/3d80c8ad-a552-4ac0-9f33-3581f781f0c3

> FDA guidance document: Considerations for Complying with 21 CFR 211110. Issue date: January 06, 2025. Get complete insights and analysis.

---

## Details

- Title: Considerations for Complying with 21 CFR 211110
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2025-01-06
- Comment Close Date: 2025-04-07
- Last Changed: 2025-01-06
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2024-D-5374">FDA-2024-D-5374</a>

## Related Documents

- [Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/real-world-evidence-considerations-regarding-non-interventional-studies-for-drug-and-biological-products/48325e39-b445-4a53-8cc0-7483dcf3e352)
- [Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities](https://www.globalkeysolutions.net/guidances/guidance-document/remote-interactive-evaluations-of-drug-manufacturing-and-bioresearch-monitoring-facilities/b3f969a3-6d17-4b51-aee6-e6cb19f8e4ba)
- [Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-design-and-conduct-of-externally-controlled-trials-for-drug-and-biological-products/9dafe0c9-19d4-48c0-a1ca-6b2a04a813ed)